<DOC>
	<DOCNO>NCT01904383</DOCNO>
	<brief_summary>Study investigate safety efficacy long-term daily use Trazenta® Tablets add-on therapy patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>PMS Trazenta Long-term Use Add-on Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus treat antidiabetic drug never treat Trazenta® Tablets ( linagliptin ) enrollment include . Exclusion criterion :</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>